Diabetes,metabolic syndrome and prostate cancer risk: Results from the EPICAP case-control study |
| |
| Affiliation: | 1. Université Paris-Saclay, UVSQ, Inserm, CESP, Exposome and Heredity Team, Villejuif, France;2. Service Urologie, Clinique Beau Soleil, Montpellier, France;3. Institut médical d′Analyse Génomique-Imagenome, Labosud, Montpellier, France;4. Registre des Tumeurs de l′Hérault, EA 2415, ICM, Montpellier, France;1. Ascension Saint Francis Hospital, 355 Ridge Ave, Evanston, IL 60202, USA;2. MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA;3. Texas Health Presbyterian Hospital Dallas, 8200 Walnut Hl Ln, Dallas, TX 75231, USA;1. Division of Endocrinology and Metabolism, Department of Internal Medicine, Dongguk University Ilsan Hospital, Goyang, South Korea;2. Department of Hematology and Medical Oncology, Kyung Hee University Hospital, School of Medicine, Kyun Hee University, Seoul, South Korea;3. Department of Pulmonary, Allergy and Critical Care Medicine, Kyung Hee University Hospital at Gangdong, School of Medicine, Kyung Hee University, Seoul, South Korea;1. Research Unit for General Practice, Aarhus, Bartholins Alle 2, 8000 Aarhus C, Denmark;2. Department of Clinical Medicine, Aarhus University, Palle Juul-Jensens Boulevard 82, 8200 Aarhus C, Denmark;1. Ontario Health (Cancer Care Ontario), 525 University Ave, Toronto, Ontario, Canada;2. Epidemiology & Biostatistics, Western University, London, Ontario, Canada;3. Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada;4. Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada;5. Division of Medical Oncology & Hematology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada;6. Department of Surgery, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada;7. Division of Thoracic Surgery, Toronto General Hospital, Toronto, Ontario, Canada;1. Department of Epidemiology, College of Public Health, University of Nebraska Medical Center, United States;2. Department of Biostatistics, College of Public Health, University of Nebraska Medical Center, United States;1. Dept. of Urology, Mount Sinai Medical Center, Miami Beach, FL, United States;2. Florida International University, Herbert Wertheim College of Medicine, Miami, FL, United States |
| |
| Abstract: | ![]()
BackgroundDiabetes may be associated with decreased prostate cancer (PCa) risk. However, previous studies have not always accounted for time since diabetes diagnosis or antidiabetic drug use. Futhermore, the role of metabolic syndrome (MetS) in PCa risk is still debated. We investigated the role of diabetes and MetS in PCa risk based on data from the Epidemiological study of PCa (EPICAP).MethodsEPICAP is a population-based case-control study that included 819 incident PCa cases in 2012–2013 and 879 controls frequency matched by age. MetS was characterized according to National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III). Logistic regression models adjusted for age, family history of PCa and ethnicity, were used to assess odds ratios (ORs) and their 95%conficence intervals (CIs) for the associations between diabetes, MetS and PCa risk.ResultsWhereas we did not observed an association between diabetes and PCa, a decreased risk of PCa has been highlighted with an increasing treated diabetes duration (p-trend=0.008). No association has been observed between MetS, the number of MetS criteria and the risk of PCa. However, we suggested that NSAIDs use could modify the association between MetS and PCa risk.ConclusionOur results suggest an inverse association between the duration of diabetes and PCa risk. The role of metabolic factors, such as MetS and its components, in PCa risk remains unclear and requires further investigations. |
| |
| Keywords: | Prostate cancer Case-control study Diabetes Metabolic syndrome NCEP-ATP III |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
